---
title: "Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Clinical trials questions"
description: "Clinical trials questions on Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results, Subgroup results, and Long-term data. Questions: Who was studied in the Ibrance PALOMA-2 trial? How long does Ibrance plus letrozole delay progression vs letrozole alone (PALOMA-2)? Does Ibrance plus letrozole help patients live longer (PALOMA-2 overall survival)? What was the response rate with Ibrance plus letrozole (PALOMA-2)? 9 further questions follow. 13 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ibrance (palbociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Clinical trials questions

Manufacturer: Pfizer Laboratories Div Pfizer Inc  
Prescribing information: [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921), [Ibrance](https://labeling.pfizer.com/ShowLabeling.aspx?id=2191)

Questions that apply to every indication of Ibrance are on [Ibrance (palbociclib), all indications](https://www.evicenter.com/medical-information/ibrance).

## Clinical trials

<a id="ibrance-paloma2-design"></a>

### Who was studied in the Ibrance PALOMA-2 trial?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “PALOMA-2 was an international, randomized, double-blind, parallel-group, multicenter study of IBRANCE plus letrozole versus placebo plus letrozole conducted in postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous systemic treatment for their advanced disease. A total of 666 patients were randomized 2:1 to IBRANCE plus letrozole or placebo plus letrozole. Randomization was stratified by disease site (visceral versus non-visceral), disease-free interval (de novo metastatic versus ≤12 months from the end of adjuvant treatment to disease recurrence versus >12 months from the end of adjuvant treatment to disease recurrence), and nature of prior (neo)adjuvant anticancer therapies (prior hormonal therapies versus no prior hormonal therapy). IBRANCE was given orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days off treatment. Patients received study treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. The major efficacy outcome of the study was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST). Additional efficacy outcome measures were confirmed overall response rate (ORR) as assessed by the investigator according to RECIST Version 1.1 and overall survival (OS).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=PALOMA%2D2%20was%20an%20international%2C%20randomized%2C,1.1%20and%20overall%20survival%20%28OS%29.)

> “Patients enrolled in this study had a median age of 62 years (range 28 to 89). The majority of patients were White (78%), and most patients had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (98%). Forty-eight percent of patients had received chemotherapy and 56% had received antihormonal therapy in the neoadjuvant or adjuvant setting prior to their diagnosis of advanced breast cancer. Thirty-seven percent of patients had no prior systemic therapy in the neoadjuvant or adjuvant setting. The majority of patients (97%) had metastatic disease. Twenty-three percent of patients had bone only disease, and 49% of patients had visceral disease.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Patients%20enrolled%20in%20this%20study,of%20patients%20had%20visceral%20disease.)

<a id="ibrance-paloma3-design"></a>

### Who was studied in the Ibrance PALOMA-3 trial?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “PALOMA-3 was an international, randomized, double-blind, parallel-group, multicenter study of IBRANCE plus fulvestrant versus placebo plus fulvestrant conducted in women with HR-positive, HER2-negative advanced breast cancer, regardless of their menopausal status, whose disease progressed on or after prior endocrine therapy. A total of 521 pre/postmenopausal women were randomized 2:1 to IBRANCE plus fulvestrant or placebo plus fulvestrant and stratified by documented sensitivity to prior hormonal therapy, menopausal status at study entry (pre/peri versus postmenopausal), and presence of visceral metastases. IBRANCE was given orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days off treatment. Pre/perimenopausal women were enrolled in the study and received the LHRH agonist goserelin for at least 4 weeks prior to and for the duration of PALOMA-3. Patients continued to receive assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. The major efficacy outcome of the study was investigator-assessed PFS evaluated according to RECIST 1.1.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=PALOMA%2D3%20was%20an%20international%2C%20randomized%2C,evaluated%20according%20to%20RECIST%201.1.)

> “Patients enrolled in this study had a median age of 57 years (range 29 to 88). The majority of patients on study were White (74%), all patients had an ECOG PS of 0 or 1, and 80% were postmenopausal. All patients had received prior systemic therapy, and 75% of patients had received a previous chemotherapy regimen. Twenty-five percent of patients had received no prior therapy in the metastatic disease setting, 60% had visceral metastases, and 23% had bone only disease.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=to%20RECIST%201.1.-,Patients%20enrolled%20in%20this%20study%20had%20a%20median%20age%20of,23%25%20had%20bone%20only%20disease.)

## Study results

<a id="ibrance-paloma2-pfs"></a>

### How long does Ibrance plus letrozole delay progression vs letrozole alone (PALOMA-2)?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “In a 2:1 randomized, double-blind, Phase 3 trial of postmenopausal women receiving first-line treatment for ER+/HER2- mBC (N=666)<sup>1</sup>*”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=In%20a%202%3A1%20randomized%2C%20double%2Dblind%2C,first%2Dline%20treatment%20for%20ER%2B%2FHER2%2D%20mBC)

> “The major efficacy outcome of the study was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST).”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20major%20efficacy%20outcome%20of,Solid%20Tumors%20Version%201.1%20%28RECIST%29.)

> “Table 12. Efficacy Results – PALOMA-2
> 	IBRANCE plus Letrozole	Placebo plus Letrozole
> CI=confidence interval; ITT=Intent-to-Treat; N=number of patients; NE=not estimable; OS=overall survival; PFS=progression-free survival.
>
> *
> Cox proportional hazards model stratified by disease site (visceral vs. non-visceral) per randomization.
> †
> Stratified log-rank test one-sided p-value.
> ‡
> Response is based on confirmed responses.
>
>
>
> Progression-free survival for ITT
>
> (investigator assessment)
>
>
>
> N=444
>
>
>
> N=222
>
>
>
>
>   Number of PFS events (%)
>
>
>
> 194 (43.7)
>
>
>
> 137 (61.7)
>
>
>
>
>   Median progression-free survival
> (months, 95% CI)
>
>
>
> 24.8 (22.1, NE)
>
>
>
> 14.5 (12.9, 17.1)
>
>
>
>
>   Hazard ratio (95% CI) and p-value
>
>
>
> 0.576 (0.463, 0.718)*, p<0.0001†”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Table%2012.%20Efficacy%20Results%20%E2%80%93,0.576%20%280.463%2C%200.718%29%2A%2C%20p%3C0.0001%E2%80%A0)

> “Unless otherwise stated, PALOMA-2 data are based on the February 2016 data cut (final prespecified analysis).”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Unless%20otherwise%20stated%2C%20PALOMA%2D2%20data,data%20cut%20%28final%20prespecified%20analysis%29.)

Note: Table 12 columns are IBRANCE plus letrozole and placebo plus letrozole, in that order.

<a id="ibrance-paloma2-overall-survival"></a>

### Does Ibrance plus letrozole help patients live longer (PALOMA-2 overall survival)?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “Overall survival (OS)<sup>2,3‡</sup>: A final OS analysis was conducted with 435 events (~65% of trial population) having occurred
> OS was not statistically significant
> Median OS was 53.8 months (95% CI: 49.8-59.2) with IBRANCE + letrozole vs 49.8 months (95% CI: 42.3-56.4) with placebo + letrozole (HR=0.92 [95% CI: 0.76-1.12]; P=0.2087)”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Overall%20survival,%28HR%3D0.92%20%5B95%25%20CI%3A%200.76%2D1.12%5D%3B%20P%3D0.2087%29)

> “November 2021 data cut.<sup>4</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=November%202021%20data)

> “Based on the prespecified final OS analysis conducted after 435 events, OS was not statistically significant.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Based%20on%20the%20prespecified%20final,OS%20was%20not%20statistically%20significant.)

<a id="ibrance-paloma2-response-rate"></a>

### What was the response rate with Ibrance plus letrozole (PALOMA-2)?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “Objective response rate (ORR)<sup>†</sup>: 55.3% (95% CI: 49.9-60.7) of patients with measurable disease achieved an objective response with IBRANCE + letrozole vs 44.4% (95% CI: 36.9-52.2) with placebo + letrozole (IBRANCE + letrozole n=338; placebo + letrozole n=171)<sup>1-3</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Objective%20response%20rate,letrozole%20n%3D338%3B%20placebo%20%2B%20letrozole)

> “ORR was defined as the number (%) of patients with confirmed complete response or partial response.”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=ORR%20was%20defined%20as%20the,complete%20response%20or%20partial%20response.)

<a id="ibrance-paloma3-pfs"></a>

### How long does Ibrance plus fulvestrant delay progression vs fulvestrant alone (PALOMA-3)?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “In a 2:1 randomized, double-blind, Phase 3 trial of women with HR+/HER2- mBC who progressed on or after endocrine therapy in the adjuvant or metastatic setting (N=521).<sup>1</sup>*”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=In%20a%202%3A1%20randomized%2C%20double%2Dblind%2C,the%20adjuvant%20or%20metastatic%20setting)

> “The major efficacy outcome of the study was investigator-assessed PFS evaluated according to RECIST 1.1.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20major%20efficacy%20outcome%20of%20the%20study%20was%20investigator%2Dassessed%20PFS,evaluated%20according%20to%20RECIST%201.1.)

> “Table 13. Efficacy Results – PALOMA-3
> CI=confidence interval; ITT=Intent-to-Treat; N=number of patients; OS=overall survival; PFS=progression-free survival.
>
> *
> Responses are based on confirmed responses.
> †
> Not statistically significant at the pre-specified 2-sided alpha level of 0.047.
> ‡
> 2-sided p-value from the log-rank test stratified by the presence of visceral metastases and sensitivity to prior endocrine therapy per randomization.
>
>
>
> IBRANCE plus Fulvestrant
>
>
>
> Placebo plus Fulvestrant
>
>
>
>
> Progression-free survival for ITT
> (investigator assessment)
>
>
>
> N=347
>
>
>
> N=174
>
>
>
>
>   Number of PFS events (%)
>
>
>
> 145 (41.8)
>
>
>
> 114 (65.5)
>
>
>
>
>   Median PFS (months, 95% CI)
>
>
>
> 9.5 (9.2, 11.0)
>
>
>
> 4.6 (3.5, 5.6)
>
>
>
>
>   Hazard ratio (95% CI) and p-value
>
>
>
> 0.461 (0.360, 0.591), p<0.0001”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Table%2013.%20Efficacy%20Results%20%E2%80%93,0.461%20%280.360%2C%200.591%29%2C%20p%3C0.0001)

> “Unless otherwise stated, PALOMA-3 data are based on the March 2015 data cut (final prespecified analysis).”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Unless%20otherwise%20stated%2C%20PALOMA%2D3%20data,data%20cut%20%28final%20prespecified%20analysis%29.)

Note: Table 13 columns are IBRANCE plus fulvestrant and placebo plus fulvestrant, in that order.

<a id="ibrance-paloma3-overall-survival"></a>

### Does Ibrance plus fulvestrant help patients live longer (PALOMA-3 overall survival)?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “Overall survival (OS): A final OS analysis was conducted with 310 events (~60% of trial population) having occurred. These data show a numerical difference in favor of IBRANCE + fulvestrant vs placebo + fulvestrant that did not reach statistical significance<sup>‡</sup>
> Median OS was 34.9 months (95% CI: 28.8-40.0) with IBRANCE + fulvestrant vs 28.0 months (95% CI: 23.6-34.6) with placebo + fulvestrant (HR=0.81 [95% CI: 0.64-1.03]; P=0.09); a difference of 6.9 months”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Overall%20survival%20%28OS%29%3A%20A%20final,a%20difference%20of%206.9%20months)

> “Based on April 2018 data cut (final OS analysis), with a median follow-up of 44.8 months.<sup>4</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Based%20on%20April%202018%20data,a%20median%20follow%2Dup%20of%2044.8)

> “After a median follow-up time of 45 months, the final OS results were not statistically significant.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=After%20a%20median%20follow%2Dup%20time,results%20were%20not%20statistically%20significant.)

<a id="ibrance-paloma3-response-rate"></a>

### What was the response rate with Ibrance plus fulvestrant (PALOMA-3)?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “Overall response rate (ORR)<sup>†</sup>: 24.6% (95% CI: 19.6-30.2) with IBRANCE + fulvestrant vs 10.9% (95% CI: 6.2-17.3) with placebo + fulvestrant in the measurable disease population (IBRANCE + fulvestrant n=267; placebo + fulvestrant n=138)”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Overall%20response%20rate,n%3D267%3B%20placebo%20%2B%20fulvestrant%20n%3D138%29)

> “ORR was defined as the number (%) of patients with confirmed complete response or partial response.”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=ORR%20was%20defined%20as%20the,complete%20response%20or%20partial%20response.)

<a id="ibrance-treatment-duration-trials"></a>

### How long did patients take Ibrance in PALOMA-2 and PALOMA-3?

> “The median duration of treatment for IBRANCE plus letrozole was 19.8 months while the median duration of treatment for placebo plus letrozole arm was 13.8 months.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20median%20duration%20of%20treatment,letrozole%20arm%20was%2013.8%20months.)

> “The median duration of treatment for IBRANCE plus fulvestrant was 10.8 months while the median duration of treatment for placebo plus fulvestrant arm was 4.8 months.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=The%20median%20duration%20of%20treatment%20for%20IBRANCE%20plus%20fulvestrant,fulvestrant%20arm%20was%204.8%20months.)

## Subgroup results

<a id="ibrance-paloma2-subgroups"></a>

### Were Ibrance plus letrozole results consistent across subgroups (PALOMA-2)?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “Consistent results were observed across patient subgroups of disease-free interval (DFI), disease site, and prior therapy. The treatment effect of the combination on PFS was also supported by an independent review of radiographs.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Consistent%20results%20were%20observed%20across,an%20independent%20review%20of%20radiographs.)

> “The graph below depicts preplanned subgroup analyses from the overall trial population in PALOMA-2. Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.”

Source: [IBRANCE: PALOMA-2 Additional Analyses, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/additional-analyses#:~:text=The%20graph%20below%20depicts%20preplanned,demonstrate%20efficacy%20in%20particular%20subgroups.)

<a id="ibrance-paloma3-subgroups"></a>

### Were Ibrance plus fulvestrant results consistent across subgroups (PALOMA-3)?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “Consistent PFS results were observed across patient subgroups of disease site, sensitivity to prior hormonal therapy, and menopausal status.”

Source: [IBRANCE: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=12921#:~:text=Consistent%20PFS%20results%20were%20observed,hormonal%20therapy%2C%20and%20menopausal%20status.)

> “The graph below depicts preplanned subgroup analyses from the overall trial population in PALOMA-3. Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.”

Source: [IBRANCE: PALOMA-3 Additional Analyses, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/additional-analyses#:~:text=The%20graph%20below%20depicts%20preplanned,demonstrate%20efficacy%20in%20particular%20subgroups.)

## Long-term data

<a id="ibrance-paloma2-long-term-side-effects"></a>

### What are the long-term side effects of Ibrance plus letrozole (PALOMA-2)?

Applies to: PALOMA-2: postmenopausal women with ER-positive, HER2-negative advanced breast cancer and no prior systemic treatment for advanced disease (IBRANCE plus letrozole vs placebo plus letrozole)

> “Selected AEs reported in the final OS analysis (with a median follow-up of 90 months) of PALOMA-2<sup>5,6††</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Selected%20AEs%20reported%20in%20the,follow%2Dup%20of%2090%20months%29%20of)

> “The most common selected adverse events (>10%, all causality)** of any grade reported in the final OS analysis of PALOMA-2 for IBRANCE + letrozole vs placebo + letrozole were neutropenia (82% vs 6%), infections (64% vs 46%), leukopenia (43% vs 3%), fatigue (41% vs 29%), nausea (38% vs 27%), alopecia (34% vs 16%), stomatitis (33% vs 15%), diarrhea (30% vs 23%), anemia (28% vs 10%), rash (22% vs 13%), thrombocytopenia (21% vs 2%), asthenia (19% vs 12%), decreased appetite (20% vs 10%), vomiting (18% vs 18%), dry skin (15% vs 7%), pyrexia (15% vs 9%), alanine aminotransferase increased (15% vs 6%), aspartate aminotransferase increased (14% vs 6%), and dysgeusia (NR vs NR)”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=The%20most%20common%20selected%20adverse%20events%20%28%3E10%25%2C%20all%20causality%29%2A%2A%20of%20any%20grade,-reported%20in%20the)

> “In an updated non-prespecified PFS analysis and the final OS analysis, no new safety signals were observed.<sup>4,5</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=In%20an%20updated%20non%2Dprespecified%20PFS,no%20new%20safety%20signals%20were)

> “Incidences of AEs are all causality, and the AEs were selected based on their designation as Adverse Reactions (ARs, treatment-related) in PALOMA-2 in the IBRANCE Prescribing Information.²”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Incidences%20of%20AEs%20are%20all,in%20the%20IBRANCE%20Prescribing%20Information.%C2%B2)

> “Based on November 2021 data cut (final OS analysis), with a median follow-up of 90 months.<sup>1,3</sup>”

Source: [IBRANCE: PALOMA-2 Efficacy & Safety, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-2/efficacy-safety#:~:text=Based%20on%20November%202021%20data,a%20median%20follow%2Dup%20of%2090)

<a id="ibrance-paloma3-long-term-side-effects"></a>

### What are the long-term side effects of Ibrance plus fulvestrant (PALOMA-3)?

Applies to: PALOMA-3: women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on or after prior endocrine therapy (IBRANCE plus fulvestrant vs placebo plus fulvestrant)

> “Selected adverse events (AEs) reported in a final OS analysis (with a median follow-up of 44.8 months) of PALOMA-3<sup>4</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Selected%20adverse%20events%20%28AEs%29%20reported,follow%2Dup%20of%2044.8%20months%29%20of)

> “With additional follow-up, no new safety signals were observed for patients treated with IBRANCE + fulvestrant.<sup>#</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=With%20additional%20follow%2Dup%2C%20no%20new,for%20patients%20treated%20with%20IBRANCE)

> “The most common selected adverse events (≥10%, all causality)** of any grade for IBRANCE + fulvestrant vs placebo + fulvestrant were neutropenia (84% vs 4%), leukopenia (60% vs 5%), infections (55% vs 35%), fatigue (44% vs 31%), nausea (36% vs 31%), anemia (32% vs 14%), stomatitis (30% vs 14%), diarrhea (27% vs 20%), thrombocytopenia (26% vs 0%), vomiting (22% vs 16%), alopecia (19% vs 6%), rash (18% vs 6%), decreased appetite (17% vs 11%), pyrexia (14% vs 6%), and aspartate aminotransferase increased (12% vs 8%)”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=The%20most%20common%20selected%20adverse,aminotransferase%20increased%20%2812%25%20vs%208%25%29)

> “In an updated non-prespecified OS analysis (with a median follow-up of 73.3 months), no new safety signals were observed.<sup>5††</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=In%20an%20updated%20non%2Dprespecified%20OS,no%20new%20safety%20signals%20were)

> “Incidences of AEs reported in this updated analysis are all causality, and the AEs were selected based on their designation as Adverse Reactions (ARs, treatment-related) in PALOMA-3 in the IBRANCE Prescribing Information.<sup>4</sup>”

Source: [IBRANCE: PALOMA-3 Efficacy & Safety Data, captured 2026-11-13](https://ibrance.pfizerpro.com/af/paloma-3/efficacy-safety#:~:text=Incidences%20of%20AEs%20reported%20in,PALOMA%2D3%20in%20the%20IBRANCE%20Prescribing)

## Related pages
- [Medical information: Ibrance (palbociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Safety](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/ibrance--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
